3.8 Article

Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations

Journal

JOURNAL OF DRUG DELIVERY
Volume 2016, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2016/3810175

Keywords

-

Funding

  1. National Institutes of Health and National Institute of Allergy and Infectious Diseases (NIAID) [U01AI068636, HHSN272201500006C]
  2. National Institutes of Health and Fogarty International Center AIDS International Training and Research and Grant (AITRP) [D43TW007991]
  3. University of Rochester Center for AIDS Research Grant [P30AI078498]
  4. University of Rochester School of Medicine and Dentistry
  5. Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant [1T32GM099607]

Ask authors/readers for more resources

Poly(lactic-co-glycolic acid) (PLGA) chitosan (CS) coated nanoparticles (NPs) were loaded with two antiretrovirals (ARVs) either lamivudine (LMV) which is hydrophilic or nevirapine (NVP) which is hydrophobic or both LMV and NVP. These ARVs are of importance in resource-limited settings, where they are commonly used in human immunodeficiency virus (HIV-1) treatment due to affordability and accessibility. NPs prepared by a water-oil-water emulsion and reduced pressure solvent evaporation technique were determined to have a positive zeta potential, a capsule-like morphology, and an average hydrodynamic diameter of 240 nm. Entrapment of NVP as a single ARV had a notable increase in NP size compared to LMV alone or in combination with LMV. NPs stored at room temperature in distilled water maintained size, polydispersity (PDI), and zeta potential for one year. No changes in size, PDI, and zeta potential were observed for NPs in 10% sucrose in lyophilized or nonlyophilized states stored at 4 degrees C and -20 degrees C, respectively. Freezing NPs in the absence of sucrose increased NP size. Drug loading, encapsulation efficiency, and kinetic release profiles were quantified by high performance liquid chromatography (HPLC). Our novel nanoformulations have the potential to improve patient outcomes and expand drug access in resource-limited countries for the treatment of HIV-1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available